Ovary/Fallopian Tube/Primary Peritoneal Cancer Studies Currently Recruiting Participants at the University of Chicago Comprehensive Cancer Center

Study Number Title
09-123-B Long Term Database Collection for Endometrial Cancer
Select
10-323-B GOG 9923: A Phase I Study of Carboplatin/Paclitaxel/CTEP-Supplied Agent Bevacizumab (NSC #704865, IND #7921) and CTEP-Supplied Agent ABT-888 (NSC #737664, IND #77840) in Newly Diagnosed Patients with Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Select
10-386-A GOG 261: A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients with Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus or Ovary
Select
10-726-A GOG 264: A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary
Select
11-0502 GOG 273: Chemotherapy Toxicity in Elderly Women with Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Select
11-0697 GOG 9927: A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888) in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Select
12-0057 A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer (Sponsor: GOG, IND# 110072)
Select
12-1560 A Randomized, Controlled, Open-Label, Phase 2 Trial of SGI-110 and Carboplatin in Subjects with Platinum-Resistant Recurrent Ovarian Cancer (SGI-110-02)
Select
12-2044 GOG 225: Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?
13-0161 Trial Participation Decision Making in Ovarian Cancer Patients and Their Families
Select
13-0492 The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multi- National, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician┐s Choice of Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum
Select
IRB13-0775 Validation of a Polygenic Neurotoxicity Risk Score in Patients with Unusually Severe Paclitaxel-Induced Neuropathy
Select
IRB13-1009 GOG 186K: A Randomized Phase II Study of NCI Supplied Cabozantinib (NSC #761968 IND #116059) Versus Weekly Paclitaxel (NSC #673089) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Select
IRB13-1000 Carboplatin, Gemcitabine, and Mifepristone for Advanced Breast Cancer and Recurrent or Persistent Epithelial Ovarian Cancer
Select
16159A GOG 213: A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab (NSC #704865, IND #7921) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary, and Fallopian Tube Cancer

To learn more about cancer clinical trials or to make an appointment, call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials). Although our objective is to provide an updated listing of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.